A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen

Michael A. Morse, Yuping Deng, Doris Coleman, Shelley Hull, Eva Kitrell-Fisher, Smita Nair, Jeffrey Schlom, Mary-Ellen Ryback, H. Kim Lyerly

Departments of Medicine [M. A. M.] and Surgery [Y. D., D. C., S. H., E. K.-F., S. N., H. K. L.], Duke University Medical Center, Durham, North Carolina 27710; NIH, Bethesda, Maryland 20852 [J. S.]; and Schering-Plough Research Institute, Kenilworth, New Jersey 07033 [M.-E. R.]

ABSTRACT

Dendritic cells (DCs), antigen-presenting cells capable of priming naive T cells to specific antigens in an HLA-restricted fashion, have been demonstrated to induce protective T cell-mediated immunity in tumor-bearing animals. We performed this study to test the safety, feasibility, and clinical response of immunizations with in vitro-generated DCs, loaded with an HLA-A2-restricted peptide fragment of the tumor antigen carcinoembryonic antigen (CEA), for the treatment of patients with advanced CEA-expressing malignancies. Cell preparations enriched for autologous DCs were generated from the patients’ plastic adherent peripheral blood mononuclear cells in serum-free media supplemented with granulocyte macrophage colony-stimulating factor and interleukin-4. Within the cell preparation, 66% of the cells expressed the phenotype typical for DCs (CD86high, HLA-DRhigh, and CD14low). The DCs were loaded with the CEA peptide CAP-1 and cryopreserved. Groups of three to six patients received four weekly or biweekly i.v. infusions of the CAP-1-loaded DC in escalating dose levels of $10^7$, $3 \times 10^7$, and $1 \times 10^8$ cells/dose. A subset of the patients in the last group also received intradermal injections of $1 \times 10^6$ to $1 \times 10^7$ DCs. There were no toxicities directly referable to the treatments. One patient had a minor response, and one had stable disease. Skin punch biopsy at DC injection sites demonstrated pleomorphic infiltrates in the three patients evaluated. We conclude that it is feasible and safe to generate and administer large numbers of previously cryopreserved DCs loaded with CAP-1 peptide to patients with advanced malignancies.

INTRODUCTION

Interest in the application of immunotherapy to the treatment of malignancies has increased with a better understanding of the two major requirements for a tumor-specific immune response: (a) the expression by tumors of unique antigens [such as CEA3 (1), MAGE-1 (2), HER-2/neu (3), MART-1 (4), and MUC1 (5)] that can be recognized by T lymphocytes; and (b) the presentation of these antigens to naive T cells in a manner that stimulates their proliferation and tumor-specific activity. DCs seem to be the most potent antigen-presenting cells (6) for inducing antitumor immunity in vitro and in vivo (7–13). The development of methods for generating large numbers of DCs from PBMCs in vitro (14–16) has now made it possible to study the application of DCs in active immunotherapy strategies for human tumors (17), and several studies (18–20) have been completed, demonstrating the possible clinical efficacy of this approach. The number of DCs used in these studies has been low (range, $1 \times 10^6$ to $1 \times 10^7$), and DCs have been administered as fresh preparations either intradermally or i.v. Because the broader application of DCs may be facilitated by the ability to generate and administer large numbers, it is important to determine whether large numbers of DCs may be generated and cryopreserved while still retaining their phenotype and function and whether administration of these larger numbers will be safe and induce a potent immune response.

We have chosen CEA as the index antigen for evaluating immune responses because of its expression by many gastrointestinal, breast, and lung adenocarcinomas (1), and immunogenicity in murine (21), primate (22), and human (23) recipients of vaccinia virus vectors carrying the CEA gene. A HLA-A2-restricted peptide fragment of CEA called CAP-1 has been shown to be a target for T cell lines derived from patients previously vaccinated with the vaccinia-CEA vector (24). On the basis of our previous demonstration that DCs loaded with CAP-1 could induce CAP-1-specific CTL activity in vitro (25), we performed a Phase I clinical trial to assess the safety and

Received 10/26/98; revised 1/28/99; accepted 2/11/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by NIH Grant U01CA72162-01 (to H. K. L.). M. A. M. is a recipient of an American Society of Clinical Oncology Career Development Award and supported by NIH Grant MO1RR00030.

2 To whom requests for reprints should be addressed, at Duke University Medical Center, Box 2606, Durham, NC 27710. Phone: (919) 681-8350; Fax: (919) 681-7970; E-mail: morse004@mc.duke.edu.

3 The abbreviations used are: CEA, carcinoembryonic antigen; DC, dendritic cell; PBMC, peripheral blood mononuclear cell; FACS, fluorescence-activated cell sorting; ANA, antinuclear antibody; ESR, erythrocyte sedimentation rate; IL, interleukin; MLR, mixed lymphocyte reaction; DTH, delayed-type hypersensitivity.
feasibility of administering escalating doses of autologous, in vitro-generated, cryopreserved DCs loaded with CAP-1 to HLA-A2-positive patients with metastatic, CEA-expressing malignancies. Patients were sequentially entered into three dose levels of CEALoaded DCs and were monitored for toxicity. In addition, the induction of in vivo CEA-specific immune responses was monitored. The results support the hypothesis that large numbers of DCs, generated in vitro in serum-free media and cryopreserved, may be safely administered and may induce in vivo antigen-specific immune responses.

**PATIENTS AND METHODS**

**Patients.** Patients were recruited from the medical and surgical oncology clinics of Duke University Medical Center from December 1996 through January 1998. For inclusion, patients were required: (a) to be HLA-A2 positive and have a metastatic cancer-expressing CEA, as defined by immunohistochemical analysis; (b) to have adequate hematological function with an absolute neutrophil count >1000 mm$^3$; an absolute lymphocyte count >1000/mm$^3$, hemoglobin >9 mg/dl, and platelets >100,000/mm$^3$; (c) to have adequate renal and hepatic function with serum creatinine <2.5 mg/dl and bilirubin <2.0 mg/dl; and (d) to have at least one recall antigen response of >3 mm on skin testing with either tetanus, mumps, *Candida, Trichophyton,* or *Histoplasma.* Exclusion criteria were: (a) chemotherapy, radiation therapy, or immunotherapy within the prior 4 weeks; (b) history of autoimmune disease, including inflammatory bowel disease; (c) presence of an active acute or chronic infection, HIV, or viral hepatitis; (d) and the use of immunosuppressives, such as azathioprine, prednisone, or cyclosporine A in the prior 4 weeks.

**Generation of DCs.** Patients were provided signed informed consent, which fulfilled Duke University Medical Center Institutional Review Board guidelines, before enrollment. Eligible patients ($n = 21$) underwent an unmobilized peripheral blood leukapheresis consisting of up to a 4.5-h processing of 7–12 liters of blood, with each collection containing a minimum of $1.0 \times 10^8$ nucleated cells/kg recipient weight. Autologous plasma (250 ml) was expressed from the leukapheresis product, which was then separated by density gradient centrifugation over Ficoll in a Cell Separator (Cobe) to obtain PBMCs. Three-quarters of the PBMCs were used to generate DCs, whereas the remainder were cryopreserved for baseline immunological studies. The PBMCs were resuspended in AIM V media (Life Technologies, Inc., Grand Island, NY) at 6 $\times 10^6$ cells/ml and plated onto T225 tissue culture flasks (60 ml/flask). The flasks were incubated in 5% CO$_2$ at 37°C, and after 2 h the nonadherent cells were harvested by vigorous washing from the flasks, and the remaining cells were cryopreserved, may be safely administered and may induce in vivo antigen-specific immune responses.

**In Vivo Immunization.** In vivo generation of cryopreserved DCs loaded with CAP-1 were monitored for toxicity. In addition, the induction of in vivo responses was monitored. The results support the hypothesis that large numbers of DCs, generated in vitro in serum-free media and cryopreserved, may be safely administered and may induce in vivo antigen-specific immune responses.

**Immunofluorescence Staining and FACS Analysis.** Before immunofluorescence staining, the viability of the cells was assessed by trypan blue exclusion. Staining and FACS analysis were performed at the Duke University Flow Cytometry Laboratory with HLA-DR-PerCp (Becton Dickinson, San Jose, CA), CD86-PE (PharMingen, San Diego, CA), and CD14-FITC (Becton Dickinson). Immunofluorescence staining was performed by washing cells with medium supplemented with 2% FCS, followed by incubation on ice for 20 min with the appropriate antibodies. Labeled cells were washed with PBS containing 2% FCS and fixed with 1% paraformaldehyde (Sigma Chemical Co., St. Louis, MO). More than 10,000 events were collected on a FACSscan using a 488 argon laser for fluorescence excitation (Becton Dickinson). Data were analyzed using CellQuest software (Becton Dickinson) on a Macintosh computer. In all experiments, isotypically stained cells were used to set cursors so that <1% of the cells were considered positive.

**Allogeneic MLR.** Allogeneic responder PBMCs (1.5 $\times 10^5$) obtained from healthy donors were cultured in RPMI 1640 supplemented with 10% fetal bovine serum or 10% human AB serum in 96-well U-bottomed tissue culture plates. Irradiated (3500 rads) DC preparations (or the patient’s PBMCs used as controls) were added in graded doses of 150–15,000 cells/well in a total volume of 200 µl. Cell proliferation after 96 h was quantified by adding 1 µCi of $[\text{methyl}^3\text{H}]$ thymidine (NEN-DuPont, Boston, MA) to each well. After 16 h, the cells were harvested onto filters, and radioactivity was measured in a scintillation counter, with results presented as the mean cpm for triplicate cultures.

**Patient Treatment.** A three-tiered dose escalation schema was used with the first three evaluable patients treated at low dose (1 $\times 10^7$ total cells/infusion for four infusions). The next six patients were treated at medium dose (3 $\times 10^7$ total cells/infusion for four infusions), and the remainder of the patients were treated at high dose (1 $\times 10^8$ total cells/infusion for four infusions). The first 12 patients were to receive the DCs i.v. over 2–3 min every week for four immunizations. The last 9 patients were to receive the DCs i.v. along with 1 $\times 10^6$ CEA peptide-loaded DCs in a volume of 0.1 ml of autologous plasma intradermally into the volar aspect of the forearm or thigh every 2 weeks for four immunizations. The last patient received IL-2 (Aldesleukine; Chiron Corporation, Emoryville, CA), 1.2 $\times 10^6$ units s.c. each day for 4 days after each DC injection.

Toxicity was graded using the standard National Cancer Institute toxicity grading scale. At the completion of all four immunizations, patients underwent a repeat leukapheresis to obtain enough cells for immunological analysis. In addition, a repeat recall antigen panel plus CAP-1 peptide at three concentrations (0.1, 1, or 10 µg/ml in 0.1 ml) was injected intradermally, and 48 h later the diameters of the erythema and indu-
ration were measured. Tumor markers (CEA, CA-125, and CA15–3) and imaging studies (computed tomography scans, bone scans, and chest radiographs) were reviewed as available before and after all four immunizations to determine the clinical response.

**Histological Analysis of Skin Biopsy Specimens.** In eight patients, the diameters of the erythema and induration at the DC intradermal injection site were measured after 48 h. In three of the patients, a 3-mm punch biopsy was performed after induction of local anesthesia with 1% lidocaine, and the skin specimen was rapidly frozen in liquid nitrogen for histological analysis. Frozen tissue sections were cut at 4 μm in a cryostat, placed on a slide, heat-fixed momentarily, and stained with H&E.

**RESULTS**

**Patient Characteristics.** The characteristics of the 21 patients initially enrolled in the study are listed in Table 1. There were 9 men and 12 women with the median age of 55 years (range, 34–82). All had CEA-expressing metastatic malignancies originating from the colon or rectum (11), breast (5), ovary (3), pancreas (1), and ampulla of Vater (1). CEA expression ranged from 50–100% for all but the ovarian cancer patients (who had 25% and 40%). The extent of disease ranged from as few as two moderately enlarged abdominal lymph nodes in a patient with ovarian cancer to multiple sites of involvement including the bones, lungs, liver, skin, and peritoneum. The median number of tissues involved was two (range, 1–3). The median Karnofsky performance scale was 80% (range, 50–100%). Although two patients had not received chemotherapy or radiotherapy, the median number of prior regimens was three (range, 0–6), including high-dose chemotherapy with autologous stem cell transplant in two women with breast cancer. Most of the patients were experiencing progression of their tumor despite chemotherapy or hormonal therapy. In those previously treated with chemotherapy or radiotherapy, a median time of 4 months (range, 1–39) had elapsed from their last treatment to the time of their leukapheresis. Two patients who had been receiving hormones (tamoxifen and megestrol acetate) for prolonged periods were allowed to remain on them at the request of their attending physicians.

**Table 1** Patient characteristics

<table>
<thead>
<tr>
<th>Patients enrolled</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Female, 12; male, 9</td>
</tr>
<tr>
<td>Age</td>
<td>Median, 55; range, 34–82</td>
</tr>
<tr>
<td>Tumor type</td>
<td>Colorectal 11, Breast 5, Ovarian 3, Pancreatic 1, Ampulla of Vater 1</td>
</tr>
<tr>
<td>Number of metastatic sites (median)</td>
<td>2 (range, 1–3)</td>
</tr>
<tr>
<td>Number of prior treatments (median)</td>
<td>2 (range, 0–6)</td>
</tr>
<tr>
<td>Elapsed time since last chemotherapy or radiotherapy</td>
<td>4 months (range, 1–39)</td>
</tr>
<tr>
<td>Karnofsky performance scale (median)</td>
<td>80% (range, 50–100%)</td>
</tr>
</tbody>
</table>

* Each organ or tissue type counts as one site (e.g., liver, bone = 2 sites of metastases); an elevated tumor marker alone, although acceptable for enrollment, was not counted as a site of disease.

**Table 2** Characteristics of DCs

<table>
<thead>
<tr>
<th>Length of leukapheresis (median)</th>
<th>3 hr, 45 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of cells collected</td>
<td>2.04 ± 0.81 × 10^6 nucleated cells/kg</td>
</tr>
<tr>
<td>PBMCs after Ficoll</td>
<td>1.03 ± 0.43 × 10^6 cells/kg</td>
</tr>
<tr>
<td>PBMCs plated</td>
<td>8.35 ± 3.30 × 10^7 cells/kg</td>
</tr>
<tr>
<td>Cells harvested (washing)</td>
<td>1.67 ± 0.71 × 10^7 cells/kg</td>
</tr>
<tr>
<td>Cells harvested (cell dissociation buffer)</td>
<td>0.07 ± 0.05 × 10^7 cells/kg</td>
</tr>
<tr>
<td>Viability (at harvest)</td>
<td>92 ± 5%</td>
</tr>
<tr>
<td>Cells remaining (after peptide loading)</td>
<td>1.43 ± 0.70 × 10^7 cells/kg</td>
</tr>
<tr>
<td>Viability (after peptide loading)</td>
<td>90 ± 8%</td>
</tr>
<tr>
<td>Cells/vial before cryopreservation</td>
<td>2.50 ± 0.77 × 10^7 cells/kg</td>
</tr>
<tr>
<td>Cells/vial thawed</td>
<td>1.37 ± 0.46 × 10^7 cells/kg</td>
</tr>
<tr>
<td>Viability of thawed cells</td>
<td>80 ± 12%</td>
</tr>
<tr>
<td>FACS analysis of cultured cells</td>
<td>CD14+ 15 ± 6%, CD86 63 ± 17%, HLA-DR 69 ± 17%</td>
</tr>
</tbody>
</table>

Because of concern that DCs might lodge in the pulmonary vasculature, causing respiratory decompensation, pulmonary function testing was required of all patients before enrollment in the study. The mean results were: forced expiratory volume (FEV) 1 77 ± 19% predicted, forced vital capacity 80 ± 20% predicted, and DlCO 88 ± 20% predicted. The lowest function for a patient who received the infusions was forced expiratory volume 39%, forced vital capacity 53%, and DlCO 83%. Preexisting organ dysfunction was not uncommon. Two patients, both with ovarian cancer, had an elevated creatinine (1.9 mg/dl and 2.3 mg/dl) because of chronic hydronephrosis and prior platinum-containing regimens. Three patients had liver function test abnormalities greater than two times the upper limit of normal due to hepatic involvement with tumor by the time of their first DC infusion.

**DC Characteristics.** All enrolled patients underwent the first leukapheresis, and DCs were successfully generated in each case. The characteristics of these DCs are listed in Table 2. The leukaphereses collected 2.04 ± 0.81 × 10^6 cells/kg and, after cell separation to remove granulocytes and erythrocytes, approximately half as many PBMCs were obtained. An average of 2.0 × 10^8 cells/kg were archived, and the remainder were used to generate DCs. After 7 days of culture, 1.67 ± 0.71 × 10^7 cells/kg, which represents ~15% of the starting number of PBMCs, were recovered with a viability of 92%. By morphology, the harvested population of cells was 60% large dendritic-like cells and 40% small lymphoid-like cells. FACS analysis of the large cell population showed that 69 ± 17% expressed high levels of HLA-DR, and 63 ± 17% expressed high levels of CD86, whereas 15 ± 6% had dim expression of CD14, consistent with DCs (Fig. 1). Sterility testing was negative for contaminants in every preparation. After cryopreservation, 54% of the DCs placed into each vial were recovered with a viability of 80% and a phenotype that was unaltered. When the function of these cryopreserved DCs was tested in the MLR, the DCs demonstrated potent alloreactivity compared with autologous PBMCs (Fig. 2). Thus, the *in vitro*-generated DC preparations used for this study were consistent with previous descriptions of DCs (14).

**Patient Treatment Characteristics.** Of the 21 individuals enrolled, 19 were evaluable for clinical response and 15
were evaluable for immunological response (Table 3). Two patients had progression of their disease between the leukapheresis and first immunization and received no therapy. Three patients received all four immunizations, but did not return for the follow-up leukapheresis required to determine their immunological response. One patient, treated at low dose, began her therapy with markedly abnormal transaminases and bilirubin due to hepatic involvement with tumor. She had progressively worsening transaminases and bilirubin by the third treatment and was removed from the study after three infusions.

There were no acute toxicities during or immediately after the DC infusions. In particular, no evidence of anaphylactic reactions or other cardiopulmonary compromise was observed. Vital signs monitored included blood pressure, temperature, pulse, cardiac rhythm, respiration, and oxygen saturation. Overall, there were no changes in these parameters, except temperature, which rose a nonsignificant 0.5°C.

There were few adverse events while patients were on the treatment phase of the study or within 1 month of their completion (Table 4). Four patients had increases in liver function test results while receiving the immunizations. Three of these patients had grade 2 abnormalities at the time of initiation of their immunizations and, by the end of the immunizations, their abnormalities had increased to grades 3 and 4. All four patients had massive involvement of their liver with tumor, and all liver test abnormalities were attributable to tumor progression. One patient with a history of Gaucher’s disease, which was manifest as mild thrombocytopenia, developed new right hip and posterior pelvic pain during the immunizations that required narcotics for control. No tumor could be identified in a biopsy of an iliac bone lesion, but Gaucher cells were seen. Thus, it is possible she experienced a flare of her Gaucher’s disease in association with the DC infusions. Of note, no patient experienced clinical signs of autoimmune disease. The one patient who received IL-2 had no adverse events other than mild skin erythema and nodule formation at the IL-2 injection sites.

The clinical response data are listed in Table 4. There was one minor response, a patient with ovarian cancer who had slight regression of small volume lymphadenopathy after the immunizations. One patient with bone lesions from breast cancer and an elevated CEA had stability of her metastases and a minimal rise in the CEA during therapy and, thus, was considered to have stable disease. The remainder of the patients experienced progressive disease by the time of their restaging studies, 1 month after completing the immunizations. One of these individuals, though, at the 2-month follow-up visit, was found to have stabilization of a liver metastasis from colorectal cancer and a small decrease in his CEA level. Subsequently, his
tumor size and CEA levels have begun to slowly increase, but at a rate slower than before enrollment in the study.

The median survival of the treated patients from the time of initiating the DC immunizations is 9 months. Twelve patients, two of whom never received the immunizations, have died since enrolling in this study. The others died between 2 and 13 months after initiating their DC infusions. The cause of death in each case was progression of the malignancy, except one patient who died while having a rod inserted into the humerus for a tumor-associated fracture approximately 1 year after her enrollment in our study.

Clinical Immunological Results. Because of the concern that immunization with DCs might cause autoimmunity, we measured the ANA, rheumatoid factor, anti-thyroglobulin, and ESR as markers of the induction of autoimmunity. Although there were no significant differences in any of these markers among all patients, there were some notable observations. The ANA was positive (at least 1:40) in 14 of the 21 patients examined before the initiation of any therapy, and the median titer in these individuals was 1:160 (range, 1:40 to 1:2560), yet none had clinically manifest autoimmune disease. After all of the DCs infusions, the ANA had increased in three patients, and remained the same in the remainder of patients tested. The rheumatoid factor was above the threshold of 30 units in only two patients before the treatment, and there was no change afterward. The anti-thyroglobulin increased in seven individuals, decreased in two patients, and remained the same in two patients after the immunizations. Although some of the increases were small, other increases were more dramatic (18–47 units, 10–153 units, and 38–148 units.) Again, there was no evidence of clinical thyroid disease, although thyroid-stimulating hormone was not measured in these individuals. Finally, the ESR was elevated in 13 of 16 patients tested before the immunizations [the median for all patients was 30 (range, 3–115), but increased in 8 patients after the immunizations (including 2 patients who did not have an elevation previously)], and the median ESR was 56 (range, 9–138.) There were no changes in the immunological parameters in the patient who received IL-2.

Other immunological parameters measured (Table 5) included: (a) the absolute lymphocyte count, which had a non-significant decrease from 1273 ± 486 to 1069 ± 288 cells/mm³ after the immunizations; and (b) the DTH response to recall antigens. Twenty patients had recall antigen responses on DTH testing before the immunizations, and of the 15 patients retested after the immunizations, 12 patients had a DTH response, including one patient who had had a negative DTH response previously. Interestingly, five patients displayed some skin site reactivity to the CEA peptide before the immunizations (induration size range, 1–5 mm). Two of these patients continued to have reactivity afterward, although none had increased in magnitude. In two patients who had reactivity before the immunizations, there was no detectable reactivity afterward, and one was not repeated, whereas one patient developed new reactivity after the immunizations (2.5 mm). Of the eight patients who received intraderal DCs loaded with CEA peptide, four had signs of skin erythema or induration ranging from 1–3 mm in diameter. We were able to compare the skin response to CEA peptide and DCs loaded with CEA peptide (DC-CEA) in three patients. In one patient with no reactivity to the CEA peptide, there was a 2-mm reactivity to the DC-CEA injection at 24 h. In the other two patients, there was no reactivity to either the peptide or the DC plus peptide injections.

Skin biopsies of DC injection sites were evaluated by H&E staining in the last three patients (one of whom had received IL-2), and all three patients were found to have a perivascular...
Immunotherapy with CAP-1-pulsed DCs

Although small-scale generation of DCs from patients with advanced malignancies is always mirror those in large clinical preparations. Previous studies on the safety of i.v. DC injections have shown that only one of the three patients was judged to have any induration or erythema at the injection site. There was no difference in the infiltrate in the patient who received IL-2, although there was a 3-mm area of induration at the DC injection site.

DISCUSSION

The purpose of this study was to evaluate the safety and feasibility of administering a number of DCs that represents the maximum that can be generated from a 4-hour leukapheresis product. We demonstrated that up to four doses of $1 \times 10^8$ mononuclear cells (enriched for DCs) could be produced, loaded with the CEA peptide CAP-1 in vitro, cryopreserved, and administered to patients with advanced malignancies.

The demonstration of the ability to generate large numbers of functional DCs from patients with advanced malignancies is an important one. Although small-scale generation of DCs in vitro has been achieved by a number of groups using either adherent PBMCs (14–16) or CD34+ cells (26–28) as the starting source, the conditions achieved in small preparations do not always mirror those in large clinical preparations. Previous human studies of DC-based immunotherapy have used lower cell numbers and freshly prepared DCs (18–20), and, thus, our study extends these observations on the safety of i.v. DC injections.

The characteristics of the cell preparations used for the immunizations in our study were consistent with previously described properties of DCs. FACS analysis demonstrated that the preparation was enriched for DCs, mixed with bystander lymphocytes. The interpatient variability in the percentage of DCs was broad, despite extensively validated, uniform cell-processing guidelines, and, thus, we believe that this represents a true difference in DC precursors or the cytokine milieu of each individual. The expression of HLA-DR and CD86 were generally high, and when CD14 expression was present it was generally low. In some cases, a separate population of cells that were CD14+ and lower in CD86 or HLA-DR could be discerned. It is not clear whether these cells are monocytes or immature DC or their precursors.

Two other important aspects of our procedure for generating DCs were the use of serum-free conditions and cryopreservation to allow for multiple injections without subjecting the patient to repeated leukaphereses. We believe serum-free conditions are necessary in clinical trials to minimize the risk of sensitizing patients to unintended antigens or introducing adventitious organisms. Although some have advocated autologous serum or plasma, we have found that this is unnecessary and, thus, prefer the serum-free condition. Cryopreservation did not significantly alter the phenotype, viability, or function of the DCs, thus, permitting reproducible conditions for each immunization.

It was also important to document the safety of administering large numbers of DCs i.v. to patients with advanced malignancies, many of whom had pulmonary involvement and risk factors for coagulopathy. A study using monocyte infusions has reported changes in coagulation parameters (29), but we saw no consistent laboratory or clinical evidence of clotting abnormalities. In fact, one of the patients had previously experienced two deep vein thromboses years earlier and had an inferior vena cava filter in place, but tolerated all infusions well. The addition of IL-2 in one patient did not lead to any discernible toxicity other than erythema and skin nodule formation at the IL-2 injection site.

The first 12 patients enrolled were treated weekly. This schedule was used because of the short life expectancy of most patients in the study. Nonetheless, in this group, DCs were cryopreserved after being generated and not infused until all tests of sterility (bacterial, fungal, Mycoplasma, and endotoxin) were reported as negative, a 4-week delay. The last nine patients received the DCs i.v. every 2 weeks for four immunizations. Patients chosen for this portion of the study were felt to be able...
to tolerate a longer period off standard therapy. At the same time, it was decided to administer the first dose of DCs fresh on the day of harvest (if a Gram’s stain was negative for organisms) because our sterility testing on the first 12 patients showed no contamination. This led to a shortening of the overall period that patients were on the treatment phase of the study.

Another area of theoretical concern was the induction of autoimmunity. CEA is found in minute amounts in the colon and has homology with nonspecific cross-reacting antigen found on granulocytes and the biliary tree (1). One safeguard was the fact that the CAP-1 peptide does not have homology with nonspecific cross-reacting antigen, thus reducing the risk of granulocytopenia. No patient experienced diarrhea or other clinical evidence of autoimmunity. It was interesting to note that 7 of 11 patients tested had an increase in the anti-thyroglobulin titer. There has been no evidence of clinical hypothyroidism, but we did not perform extensive laboratory studies of thyroid function. Approximately 2% of the adult population are thought to have antithyroid antibodies, in the absence of clinical hypothyroidism (30). A study of patients with pancreatic adenocarcinoma reported 24% had antithyroid antibodies (31). The increase in ESR in our study may reflect increased inflammatory response either due to tumor progression or in response to the immunizations.

Although not a primary objective of this study, induction of CAP-1-specific immune responses in vivo was identified in preliminary studies. The data showing CAP-1-specific T cell activity measured in the peripheral blood will be presented elsewhere. In four of the eight patients receiving intradermal injections with DCs loaded with CAP-1, there were measurable areas of erythema and induration. These areas were biopsied in three patients and showed pleomorphic perivascular infiltrates consistent with a DTH response, despite the fact that in two of the individuals, no erythema or induration was observed. This indicates that lack of an obvious DTH response on visual inspection of the skin does not preclude a measurable response on microscopic exam. Of interest was the fact that CAP-1 peptide alone induced measurable areas of erythema and induration in some patients, even before receiving the DC immunizations. In two patients with no reactivity before the immunizations, there was skin reactivity afterward. This is particularly interesting because the DTH response is generally thought to be class II-dependent, but the CEA peptide is class I-restricted. In murine models, though, class I-restricted peptides have been shown to elicit DTH-like reactions (32), consisting of infiltration with CD8+ cells.

The safety and the feasibility of the immunizations provide the background for further studies of active immunotherapy with DCs. Detailed characterization of the T-cell response to the immunizations is ongoing, as are efforts to improve the function of the DCs, including applying maturation signals such as CD40-ligand (33). Also, because animal models demonstrate the efficacy of active immunotherapy in the setting of minimal tumor burden, we are now studying the application of DC-based immunotherapy in human settings of minimal residual disease. We administered IL-2 to one patient in a “pilot” fashion and observed no increase in toxicity at the doses used. Further evaluation of the role of adjuvant cytokines is also necessary.

ACKNOWLEDGMENTS

We thank Karen Mann and the technicians of the Duke University Medical Center Flow Cytometry Laboratory for performing the FACS analysis of the DCs and Dr. Jeffrey Platt and Pamela High for staining the skin biopsy specimens.

REFERENCES


A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen

Michael A. Morse, Yuping Deng, Doris Coleman, et al.